This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease (ANAVEX)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Anavex Life Sciences Corp.
ClinicalTrials.gov Identifier:
NCT02244541
First received: August 31, 2014
Last updated: August 10, 2016
Last verified: August 2016
History of Changes
  Purpose
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship between dosing regimen and pharmacodynamics efficacy outcomes and to evaluate the bioavailability of the oral form used and to explore the relationship of ANAVEX2-73 as add-on therapy to AD standard of care.

Condition Intervention Phase
Alzheimer's Disease Drug: ANAVEX2-73 Oral Drug: ANAVEX2-73 Intravenous Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Anavex Life Sciences Corp.:

Primary Outcome Measures:
  • To determine maximum tolerated dose of Anavex2-73. [ Time Frame: 36 Days ]

Secondary Outcome Measures:
  • PK sampling- blood test results [ Time Frame: First part (PART A), first period (hours): 1, 48, 264; second period (hours): 1, 72, 264; extension period (PART B): Week 1, 12 and 26. ]
  • Mini-mental state examination score (MMSE) [ Time Frame: Baseline, and during the extension period at Week 1, 12, 26, 36, 48, and 52 ]
  • Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory) [ Time Frame: Baseline, and during the extension period at Week 1, 12, 26, 36, 48, and 52 ]
  • Cogstate Brief Battery (CBB) Score and International Shopping List Task (ISLT) Score [ Time Frame: At baseline, Day 1, 2, 6, 9, 12 of Period 1 and Day 1, 2, 6, 9, 12 of Period 2 and during the extension period at Week 12, 36, 48, and 52. ]
  • Electroencephalographic activity, including event-related potentials (EEG/ERP) [ Time Frame: baseline, Day 1, 5, 11 of Period 1 and Day 1, 5, 11 of Period 2 and, Week 12, 36, 48, and 52 of the extension period ]
  • Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score [ Time Frame: Baseline at Period 1 ]
  • Rosen Modified Hachinski Ischemic Score (RM/HIS10) [ Time Frame: Baseline at period 1 ]
Estimated Enrollment: 32
Study Start Date: December 2014
Estimated Study Completion Date: October 2016
Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anavex2-73 oral then the Anavex2-73 intravenous formulation
Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
 Drug: ANAVEX2-73 Oral Drug: ANAVEX2-73 Intravenous
Experimental: Anavex2-73 intravenous then the Anavex2-73 oral formulation
Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
 Drug: ANAVEX2-73 Oral Drug: ANAVEX2-73 Intravenous
Experimental: Anavex2-73 30 mg oral formulation
Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
 Drug: ANAVEX2-73 Oral
30 mg hard gelatin capsule
Experimental: Anavex2-73 50 mg oral formulation
Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
 Drug: ANAVEX2-73 Oral
50 mg hard gelatin capsule

Detailed Description:

This is a Phase 2a study consisting of two parts, PART A and PART B. The first part (PART A) is a simple randomised, open-label, 2-period, cross-over, adaptive design study lasting for each participant up to 36 days.

The second part (PART B) is an open-label extension for an additional period of 52 weeks, so as to establish a longer drug effect for the participants who wish to continue on oral daily dose.

The complete timeline of the study includes the screening assessments within 28 days prior to simple randomisation and initiation of the study. The first administration of study medication will occur after all baseline and screening procedures have been passed (baseline is defined as pre-dosing period timeframe day -28 to day -1). No study procedures will be undertaken until a current informed consent form has been signed by each participant or their respective carer or responsible person.

The design of the first part (PART A) of the study involves two periods, two administration routes and two dose levels: In one period the intravenous (iv) form will be given and in the other period the oral dose will be given. The first period will involve 12 administrations (either oral or iv) and the second period will involve 11 administrations (either oral or iv).

The very first administration in the first period is intended as a full pharmacokinetic (PK) screen over the first 48 hours (Day 1 to Day 3). After that, 11 daily administrations complete the first period (Day 3 to Day 13). After a wash-out period of 11 days, the second period of the study starts, involving again 11 daily administrations. Therefore, the first part (PART A) of the study is scheduled to be completed in 36 days.

The study design asks for 32 participants, 16 males and 16 female participants. All participants have the option to go on to the second part (PART B) of the study, the extended open-label study exploring the cognitive effect of the drug for another 52 weeks where the oral form will be exclusively administered.

Safety and tolerability will be constantly assessed throughout the study, starting from the first dose of study medication.

  Eligibility
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  1. Diagnosis of Probable AD in accordance with NINCDS-ADRDA criteria.
  2. A brain CT or MRI scan performed within last 12 months from day of screening consistent with the clinical diagnosis of probable AD.
  3. Age from 55 to 85 years inclusive.
  4. MMSE score of 16-28 inclusive.
  5. Rosen Modified Hachinski Ischemic score <=4.
  6. Community dwelling with caregiver who has regular contact with the subject for at least 10 hours per week and is able to oversee the patient's compliance with study medication and participate in the patient's clinical assessment and is capable of accompanying the participant on all clinic visits.
  7. Fluency in English.
  8. Be able to read, write, speak clearly for the cognitive tests, with eyesight and hearing sufficient to enable completion of the cognitive tests.
  9. Receiving stable doses of medications for the treatment of non-excluded medical conditions for at least 30 days prior to screening.

Main Exclusion Criteria:

  1. Dementia other than AD such as AIDS, CJD, LBD, CVD, Progressive Supranuclear Palsy, Multiple cerebral infarcts, or normal pressure hydrocephalus.
  2. Other neurodegenerative diseases, including Parkinson's disease and Huntington's disease, or cerebral tumour.
  3. Current presence of a clinically significant major psychiatric disorder according to the criteria of the DSM-IV, or symptom that could affect the participant's ability to complete the study). HAM-D score >12.
  4. Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study.
  5. Any other criteria which in the opinion of the Investigator causes the participant not to qualify for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02244541

Locations
Australia, Victoria
Melbourne Health - The Royal Melbourne Hospital
Melbourne, Victoria, Australia, 3050
Austin Health - Heidelberg Repatriation Hospital
Melbourne, Victoria, Australia, 3084
Caulfield Hospital
Melbourne, Victoria, Australia, 3162
Nucleus Network- Centre for Clinical Studies
Melbourne, Victoria, Australia
St. Vincent's Hospital
Melbourne, Victoria, Australia
Sponsors and Collaborators
Anavex Life Sciences Corp.
Investigators
Principal Investigator: Stephen Macfarlane Caulfield Hospital
  More Information

Responsible Party: Anavex Life Sciences Corp.
ClinicalTrials.gov Identifier: NCT02244541     History of Changes
Other Study ID Numbers: ANAVEX2-73-002
Study First Received: August 31, 2014
Last Updated: August 10, 2016

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on July 13, 2017